MP1: a novel enzyme for bio-manufacturing Adipic Acid
MP1: a novel enzyme for bio-manufacturing Adipic Acid
批准号:
10016171
负责人:
金额:
$44.59万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2022
资助国家:
英国
项目状态:
已结题
起止时间:
2022 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
**PROBLEM:** Adipic acid (ADP; aka hexanedioic acid) is an important chemical. It is used for manufacturing many common materials including polyurethanes, plasticisers used in PVC production, and Nylon 6,6 (which consumes ~75% of all ADP made).ADP is manufactured via a multi-step reaction:* Benzene is reduced to cyclohexane at high-pressures and high temperatures using a catalyst (e.g., Ni/Al2O3) and a hydrogen feed.* Cyclohexane is oxidized using air plus a metal catalyst (e.g., cobalt) to generate a cyclohexanone and cyclohexanol mixture (KA oil).* KA oil is oxidized with nitric oxide and copper/ammonium metavanadate to produce ADP \[conversion yield ~95%\].Industrial ADP manufacturing causes significant environmental problems:* Around 10% of global nitric oxide (NOx) emissions are from ADP production.* The benzene feedstock is a non-renewable petroleum compound and volatile carcinogen.* Spent metal catalysts create toxic waste streams.**OPPORTUNITY:** Mellizyme are engineering a novel enzyme 'MP1' and have recently identified that it exhibits activity that enables the conversion of cyclohexane to ADP in air, enabling a greener ADP manufacturing method.**KEY PROJECT OBJECTIVES:** Deploy synthetic biology approaches to engineer MP1 to increase its thermostability, conversion rate speed, and diminish the formation of unwanted by-products. The project outputs will help Mellizyme to plan a future collaborative industrial demonstrator project showing how MP1 can be used at-scale for industrial ADP manufacturing.**STATE-OF-THE-ART LIMITATIONS*** Chemosynthetic methods of ADP manufacture suffer low conversion rates of cyclohexane and selectivity issues, leading to the formation of diacid contaminants, posing purification problems.* Catalytic degradation of NOx requires additional capital and energy expenditures.* Biomass-derived routes frequently require expensive precious metal catalysts.**MP1 INNOVATIONS/USPs*** MP1 works at atmospheric pressure and at a lower temperature than existing methods. This significantly reduces the energy requirement for ADP manufacturing using MP1 when compared to the high-pressures and high temperatures needed for the usual routes by which ADP is manufactured.* MP1 removes the need for metal catalysts, preserving rare metals, and stopping toxic metal waste formation.* Zero NOx production, supporting net zero targets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
Novel-miR-1134调控LHCGR的表达介导拟
穴青蟹卵巢发育的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:崔文晓
-
依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
-
批准号:82304677
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:边兴博
-
依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
-
批准号:82304658
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:刘亚
-
依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
-
批准号:32102747
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:李婉雁
-
依托单位:
novel_circ_001042/miR-298-5p/Capn1轴调节线粒体能量代谢在先天性肛门直肠畸形发生中的作用机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:唐晓冰
-
依托单位:
novel-miR-59靶向HMGAs介导儿童早衰症细胞衰老的作用及机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:58万元
-
批准年份:2021
-
负责人:张瑜
-
依托单位:
novel_circ_008138/rno-miR-374-3p/SFRP4调控Wnt信号通路参与先天性肛门直肠畸形发生的分子机制研究
-
批准号:82070530
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:白玉作
-
依托单位:
miRNA-novel-272通过靶向半乳糖凝集素3调控牙鲆肠道上皮细胞炎症反应的机制研究
-
批准号:32002421
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:修云吉
-
依托单位:
m6A修饰介导的lncRNA WEE2-AS1转录后novel-pri-miRNA剪切机制在胶质瘤恶性进展中的作用研究
-
批准号:82072775
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:薛皓
-
依托单位:
miRNA/novel_167靶向抑制Dmrt1的表达在红鳍东方鲀性别分化过程中的功能研究
-
批准号:31902347
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2019
-
负责人:闫红伟
-
依托单位: